The PowerAtlas: a power and sample size atlas for microarray experimental design and research

BMC Bioinformatics
Grier P PageDavid B Allison

Abstract

Microarrays permit biologists to simultaneously measure the mRNA abundance of thousands of genes. An important issue facing investigators planning microarray experiments is how to estimate the sample size required for good statistical power. What is the projected sample size or number of replicate chips needed to address the multiple hypotheses with acceptable accuracy? Statistical methods exist for calculating power based upon a single hypothesis, using estimates of the variability in data from pilot studies. There is, however, a need for methods to estimate power and/or required sample sizes in situations where multiple hypotheses are being tested, such as in microarray experiments. In addition, investigators frequently do not have pilot data to estimate the sample sizes required for microarray studies. To address this challenge, we have developed a Microrarray PowerAtlas. The atlas enables estimation of statistical power by allowing investigators to appropriately plan studies by building upon previous studies that have similar experimental characteristics. Currently, there are sample sizes and power estimates based on 632 experiments from Gene Expression Omnibus (GEO). The PowerAtlas also permits investigators to upload thei...Continue Reading

References

May 18, 2001·Genetical Research·M K Kerr, G A Churchill
May 31, 2001·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·M K KerrG A Churchill
Dec 26, 2001·Nucleic Acids Research·Ron EdgarAlex E Lash
Oct 22, 2002·Science·Catherine A BallUNKNOWN Microarray Gene Expression Data (MGED) Society
Nov 19, 2002·Statistics in Medicine·Mei-Ling Ting Lee, G A Whitmore
Feb 12, 2004·Arthritis and Rheumatism·Huang-Ge ZhangJohn D Mountz
Dec 8, 2004·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Sue-Jane Wang, James J Chen

❮ Previous
Next ❯

Citations

Apr 19, 2011·Briefings in Bioinformatics·Zhide Fang, Xiangqin Cui
Nov 19, 2008·Bioinformatics·Adam L AsareVicki Seyfert-Margolis
Jun 17, 2009·Bioinformatics·Kathleen F Kerr
Dec 17, 2008·Journal of Applied Physiology·David L AllenJeremy L Barth
Jun 5, 2010·PLoS Computational Biology·Mark Reimers
Jun 6, 2008·International Journal of Plant Genomics·Grier P Page, Issa Coulibaly
Mar 18, 2010·The Journal of Nutritional Biochemistry·Wenjiang J FuGuoyao Wu
Aug 31, 2006·Journal of Leukocyte Biology·Malavika S GiriLuis J Montaner
Dec 29, 2006·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Anna ContiAntonio Faiella
May 15, 2008·BJU International·Bin K KroonLaura J van't Veer
Oct 22, 2008·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Tania DasBanerjeeStephen V Faraone
Sep 20, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael S BreenStephen J Glatt
Apr 26, 2019·Scientific Reports·K L Bowlt BlacklockM Starkey
Feb 5, 2014·Cold Spring Harbor Protocols·Manuel Ares

❮ Previous
Next ❯

Datasets Mentioned

BETA
GDS

Methods Mentioned

BETA
chip
chips

Software Mentioned

GLG
Excel
GEO
PowerAtlas

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.